Amgen Closes In on a Home Run

Amgen (Nasdaq: AMGN  ) already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park. Shares are soaring as well, up 15% so far today.

In a phase 3 head-to-head trial, denosumab worked better than Novartis' (NYSE: NVS  ) Zometa in treating the bones of breast cancer patients whose cancer had spread to the bone (which can weaken and destroy the bone around the tumor). The extra indication beyond osteoporosis could result in a landslide of additional sales. After all, Novartis sold $1.4 billion worth of Zometa last year treating the same indication.

Amgen held back most of the data so that it can present it at a scientific meeting, but the company did say that the drug produced a few cases of osteonecrosis of the jaw (ONJ). The side effect, which causes the jaw to deteriorate, has been seen in patients taking Zometa. The best-case scenario was that denosumab wouldn't have the side effect, but, given the better efficacy, an apparently equivalent side-effect profile is an acceptable outcome.

We'll get a better idea of what the FDA thinks of denosumab for osteoporosis in August when the agency holds an advisory panel meeting, but the chances for approval seem pretty good considering the data.

The prospects for marketing success for denosumab as an osteoporosis treatment, on the other hand, are a little less clear. There are a lot of drugs available to treat osteoporosis -- including Roche and GlaxoSmithKline's (NYSE: GSK  ) Boniva, Novartis' Reclast, Eli Lilly's (NYSE: LLY  ) Evista and Forteo, and generic versions of Merck's (NYSE: MRK  ) Fosamax -- and it's not clear that denosumab's efficacy is enough to get doctors to switch en masse.

But yesterday's cancer data should easily push denosumab into blockbuster status, assuming the other trials Amgen is running in cancer patients turn out similar results.

With slumping sales of its anemia drugs, Amgen really needs denosumab to hit a home run. It's not there yet, but yesterday's news helped it get a little closer to going over the fence.

This Foolishness could help you find your next home run stock:

  • It only takes three years to hit a home run.
  • Prime is the new subprime.
  • Despite being well off the March lows, there's still good buys out there.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., likes to print out The Fool's disclosure policy, wad it up, and use it as an office baseball. He doesn't own shares of any company mentioned in this article. Novartis is a Motley Fool Global Gains selection.


Read/Post Comments (0) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 936655, ~/Articles/ArticleHandler.aspx, 4/24/2014 7:39:58 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASD 4,126.97 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/23/2014 3:59 PM
AMGN $113.32 Down -5.99 -5.02%
Amgen, Inc. CAPS Rating: ****
GSK $55.14 Down -0.16 -0.29%
GlaxoSmithKline CAPS Rating: ***
LLY $59.56 Down -0.47 -0.78%
Eli Lilly & Co. CAPS Rating: ***
MRK $57.50 Down -0.27 -0.47%
Merck & Co., Inc. CAPS Rating: ***
NVS $86.17 Down -0.39 -0.45%
Novartis CAPS Rating: *****

Advertisement